Naccarelli Gerald V
Division of Cardiology and Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Curr Opin Cardiol. 2004 Jul;19(4):317-22. doi: 10.1097/01.hco.0000129666.57492.45.
This article reviews multiple secondary and primary prevention trials that have expanded the indications for implantable cardioverter-defibrillators (ICDs).
Most studies performed over the last several years have concentrated on the role of ICDs in high-risk patients for the primary prevention of sudden death. Several recent trials that have been completed but not published are also reviewed.
Data from recently completed trials and evolving ICD technology, such as ICDs with cardiac resynchronization capabilities, will alter indications for ICDs in the near future.
本文回顾了多项扩大植入式心脏复律除颤器(ICD)适应证的二级和一级预防试验。
过去几年进行的大多数研究都集中在ICD在高危患者一级预防心源性猝死中的作用。还回顾了几项已完成但未发表的近期试验。
近期完成试验的数据以及不断发展的ICD技术,如具有心脏再同步功能的ICD,将在不久的将来改变ICD的适应证。